The 36-month beta value for ATAI is at 1.18. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATAI is 124.98M, and currently, shorts hold a 9.05% of that float. The average trading volume for ATAI on February 24, 2025 was 2.62M shares.
ATAI) stock’s latest price update
The stock of ATAI Life Sciences N.V (NASDAQ: ATAI) has decreased by -10.55 when compared to last closing price of 1.99.Despite this, the company has seen a loss of -22.61% in its stock price over the last five trading days. 247wallst.com reported 2025-02-23 that Biotech companies saw the most notable insider purchases of the past week, including at the latest of the recent handful of biotech initial public offerings.
ATAI’s Market Performance
ATAI’s stock has fallen by -22.61% in the past week, with a monthly rise of 17.88% and a quarterly rise of 2.89%. The volatility ratio for the week is 11.92% while the volatility levels for the last 30 days are 14.72% for ATAI Life Sciences N.V The simple moving average for the last 20 days is -10.93% for ATAI’s stock, with a simple moving average of 21.93% for the last 200 days.
Analysts’ Opinion of ATAI
Many brokerage firms have already submitted their reports for ATAI stocks, with H.C. Wainwright repeating the rating for ATAI by listing it as a “Buy.” The predicted price for ATAI in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on November 18, 2024 of the previous year 2024.
Maxim Group, on the other hand, stated in their research note that they expect to see ATAI reach a price target of $6. The rating they have provided for ATAI stocks is “Buy” according to the report published on April 03rd, 2024.
Loop Capital gave a rating of “Buy” to ATAI, setting the target price at $18 in the report published on November 01st of the previous year.
ATAI Trading at 7.55% from the 50-Day Moving Average
After a stumble in the market that brought ATAI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.54% of loss for the given period.
Volatility was left at 14.72%, however, over the last 30 days, the volatility rate increased by 11.92%, as shares surge +15.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.06% upper at present.
During the last 5 trading sessions, ATAI fell by -20.46%, which changed the moving average for the period of 200-days by -13.71% in comparison to the 20-day moving average, which settled at $2.0010. In addition, ATAI Life Sciences N.V saw 33.83% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATAI starting from Apeiron Investment Group Ltd., who purchase 10,835,718 shares at the price of $2.10 back on Feb 14 ’25. After this action, Apeiron Investment Group Ltd. now owns 40,555,215 shares of ATAI Life Sciences N.V, valued at $22,755,008 using the latest closing price.
ATAI Life Sciences N.V., the 10% Owner of ATAI Life Sciences N.V, sale 2,660,000 shares at $6.05 during a trade that took place back on Sep 26 ’24, which means that ATAI Life Sciences N.V. is holding 6,905,774 shares at $16,093,000 based on the most recent closing price.
Stock Fundamentals for ATAI
Current profitability levels for the company are sitting at:
- -319.87 for the present operating margin
- 0.2 for the gross margin
The net margin for ATAI Life Sciences N.V stands at -388.53. The total capital return value is set at -0.6. Equity return is now at value -62.43, with -50.86 for asset returns.
Based on ATAI Life Sciences N.V (ATAI), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at -3.33. The debt to equity ratio resting at 0.16. The interest coverage ratio of the stock is -36.98.
Currently, EBITDA for the company is -36.31 million with net debt to EBITDA at 0.05. When we switch over and look at the enterprise to sales, we see a ratio of 1027.56. The receivables turnover for the company is 0.06for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.81.
Conclusion
In conclusion, ATAI Life Sciences N.V (ATAI) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
